|
End-of-day quote
Thailand S.E.
2026-08-25
|
5-day change | 1st Jan Change | ||
| 5.050 THB | +1.41% |
|
-7.34% | +9.78% |
Company Valuation: Inter Pharma
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 2,699 | 5,811 | 5,513 | 3,353 | 1,949 | 2,785 |
| Change | - | 115.34% | -5.13% | -39.19% | -41.86% | 42.86% |
| Enterprise Value (EV) 1 | 2,666 | 5,993 | 5,275 | 3,339 | 2,158 | 2,904 |
| Change | - | 124.78% | -11.98% | -36.69% | -35.37% | 34.56% |
| P/E | 50.2x | 54.2x | 40.6x | 66x | 52.3x | 22.8x |
| PBR | 5.73x | 7.63x | 2.86x | 1.75x | 1.01x | 1.35x |
| PEG | - | 0.6x | 33.47x | -1.1x | -2x | 0x |
| Capitalization / Revenue | 6.04x | 6.31x | 3.59x | 1.86x | 1.02x | 1.26x |
| EV / Revenue | 5.97x | 6.51x | 3.44x | 1.86x | 1.13x | 1.31x |
| EV / EBITDA | 32.4x | 35x | 25.3x | 19.9x | 15.6x | 10.7x |
| EV / EBIT | 34x | 41.1x | 30.7x | 30.5x | 28.6x | 15.1x |
| EV / FCF | 112x | -18.9x | 134x | -63.8x | -22.3x | 31.7x |
| FCF Yield | 0.89% | -5.3% | 0.75% | -1.57% | -4.48% | 3.16% |
| Dividend per Share 2 | 0.0103 | - | 0.1108 | 0.0214 | - | 0.073 |
| Rate of return | 0.18% | - | 1.22% | 0.39% | - | 1.59% |
| EPS 2 | 0.1147 | 0.2214 | 0.2241 | 0.0839 | 0.0616 | 0.2022 |
| Distribution rate | 8.98% | - | 49.4% | 25.5% | - | 36.1% |
| Net sales 1 | 446.9 | 921 | 1,534 | 1,799 | 1,912 | 2,214 |
| EBITDA 1 | 82.3 | 171.4 | 208.7 | 167.7 | 138.3 | 272.5 |
| EBIT 1 | 78.5 | 145.8 | 171.7 | 109.4 | 75.53 | 192 |
| Net income 1 | 53.78 | 105.2 | 119.2 | 50.79 | 37.28 | 122.4 |
| Net Debt 1 | -32.53 | 181.5 | -238.3 | -13.3 | 208.9 | 119.3 |
| Reference price 2 | 5.758 | 12.000 | 9.108 | 5.538 | 3.220 | 4.600 |
| Nbr of stocks (in thousands) | 468,650 | 484,267 | 605,346 | 605,346 | 605,344 | 605,344 |
| Announcement Date | 2/25/21 | 2/25/22 | 2/28/23 | 3/1/24 | 2/25/25 | 3/2/26 |
1THB in Million2THB
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 35.49x | 12.87x | 26.08x | 0.56% | 1,111B | ||
| 30.37x | - | - | 1.97% | 658B | ||
| 33.76x | 7.81x | 16.23x | 2.59% | 467B | ||
| 20.64x | 4.89x | 12.12x | 2.7% | 369B | ||
| 22.46x | 5.78x | 14.33x | 2.76% | 301B | ||
| 21.25x | 4.36x | 12.44x | 2.02% | 256B | ||
| 28.07x | 7.23x | 12.84x | 2.27% | 240B | ||
| 13.6x | 4.83x | 10.09x | 3.78% | 207B | ||
| -44.84x | 6.47x | 25.28x | 2.25% | 182B | ||
| Average | 17.87x | 6.78x | 16.18x | 2.32% | 421.22B | |
| Weighted average by Cap. | 25.43x | 8.47x | 18.61x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IP Stock
- IP-R Stock
- Valuation Inter Pharma
Select your edition
All financial news and data tailored to specific country editions
















